Partners Elan Corp. plc and Wyeth said they plan to begin Phase III testing of their lead immunotherapeutic candidate bapineuzumab (AAB-001) for mild to moderate Alzheimer's disease in the second half of this year, boosting excitement around the disease-modifying agent. (BioWorld Today)
Partners Elan Corp. plc and Wyeth said they plan to begin Phase III testing of their lead immunotherapeutic candidate bapineuzumab (AAB-001) for mild to moderate Alzheimer's disease in the second half of this year, boosting excitement around the disease-modifying agent. (BioWorld Today)
GAITHERSBURG, Md. - FluMist should be used in children between 1 and 5 years old, a majority of FDA advisors recommended Wednesday, supporting MedImmune Inc.'s bid to expand use of the live influenza virus vaccine. (BioWorld Today)
GAITHERSBURG, Md. - FluMist should be used in children between 1 and 5 years old, a majority of FDA advisors recommended Wednesday, supporting MedImmune Inc.'s bid to expand use of the live influenza virus vaccine. (BioWorld Today)
Sales of Amgen Inc.'s blockbuster EPO products are facing a further downturn, this time thanks to the Centers for Medicare & Medicaid Services (CMS), and the company's stock on Tuesday lost 3.7 percent as a result. (BioWorld Today)
